Biotechnology

Entrada Therapeutics

Entrada Therapeutics released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 875K (forecast USD 2.919M), actual EPS USD -0.9499 (forecast USD -1.0885)

Guggenheim analyst maintains buy rating on Entrada Therapeutics

Entrada Therapeutics released FY2025 earnings on February 26 (EST), actual revenue USD 25.42 M (forecast USD 30.45 M), actual EPS USD -3.4746 (forecast USD -3.7583)

Entrada Therapeutics Releases Corporate Presentation on Gene Therapy Pipeline

H.C. Wainwright Reiterates Buy Rating on Entrada Therapeutics

Entrada Therapeutics released FY2025 9 Months Earnings on November 6 (EST), actual revenue USD 24.12 M, actual EPS USD -2.5294

Entrada Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 1.614 M (forecast USD 8.621 M), actual EPS USD -1.0644 (forecast USD -0.99)

Entrada Therapeutics released FY2025 Semi-Annual earnings on August 6 (EST), actual revenue USD 22.51 M, actual EPS USD -1.47

Entrada Therapeutics released FY2025 Q2 earnings on August 6 (EST), actual revenue USD 1.95 M (forecast USD 8.167 M), actual EPS USD -1.0426 (forecast USD -0.8475)

5AM Ventures Reports Sale of Entrada Therapeutics Common Stock

Entrada Therapeutics Held 2025 Annual Shareholders' Meeting

Entrada Therapeutics Announces Inducement Grant

Nuveen reduces holdings in Entrada Therapeutics

Entrada Therapeutics Appoints Maha Radhakrishnan to its Board of Directors

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Rule

Entrada Therapeutics launches clinical trial for Duchenne muscular dystrophy

Entrada Therapeutics released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 20.56 M (forecast USD 10.17 M), actual EPS USD -0.4223 (forecast USD -0.788)

Entrada Therapeutics reports Q1 2025 net loss of $17.3 million

Entrada Therapeutics Inc Expected to Report Quarterly Loss of 79 Cents and 82.8% Revenue Drop

Entrada Therapeutics Sees Significant Layoffs to Focus on DMD Project

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

TRDA

Entrada Therapeutics Inc. reported a transformational year with five clinical-stage programs in Duchenne muscular dystrophy and myotonic dystrophy type 1. The company highlighted positive early safety signals and a strong pipeline in inherited retinal diseases, with sufficient capital to fund operations into Q3 2027. Analysts rate TRDA stock as a Buy with a $10.00 price target, though concerns about financial performance and technicals persist. The company focuses on genetic medicines for high unmet need diseases, leveraging its EEV delivery platform.

Tip Ranks

Vertex Pharma

Entrada Therapeutics Highlights Transformational Year and Pipeline Progress

Entrada Therapeutics updated its corporate presentation, highlighting favorable safety and significant functional gains in ENTR-601-44 Cohort 1 for DMD. Cohort 2 data is expected by year-end 2026, with ongoing dosing. The company anticipates multiple catalysts in 2026 and has a cash runway into Q3 2027.

TradingView

Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026

Pomerantz Law Firm is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (NASDAQ: TRDA) regarding potential securities fraud or unlawful business practices. Following a press release on May 7, 2026, announcing clinical study results that were deemed 'positive' but showed only a 2.36% increase in dystrophin production, Entrada's stock plummeted by 57.27%. Investors are encouraged to contact Pomerantz for more information.

prnewswire

22:30 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

Entrada Therapeutics' shares plummeted over 55% after disappointing early data for its Duchenne muscular dystrophy treatment, ENTR-601-44. While the Phase 1/2 study indicated positive safety and tolerability, the increase in dystrophin production was only 2.36%, far below the expected 10%. Investors were disheartened, especially compared to Avidity Biosciences' 25% increase with its therapy. The company may need to explore higher doses to remain competitive, as the FDA previously halted its human trials until February 2025. Duchenne muscular dystrophy affects around 41,000 individuals in the U.S. and Europe, primarily children and males.

biopharmadive

Atrium Therapeutics

NOVARTIS AG

Novartis AG

Entrada shares dive as Duchenne results disappoint

Entrada Therapeutics (NASDAQ: TRDA) reported promising initial data from its phase I/II ELEVATE-44-201 trial for Duchenne muscular dystrophy (DMD), showing favorable safety and early functional improvements in patients. The trial met its primary objective with mild adverse events and no serious safety concerns. Notably, treated participants exhibited significant improvements in motor function. The company aims for accelerated approval and anticipates further clinical milestones in 2026, with ongoing studies evaluating higher doses and additional cohorts.

Market Beat

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly earnings of ($0.95) EPS, beating estimates by $0.11. Revenue was $0.88 million, below the expected $2.92 million. The company has a negative return on equity of 39.83% and a net margin of 565.48%. Despite positive safety results in clinical trials, the stock fell 57.3% to $6.85. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a target price of $19.00. Financial concerns persist as the net loss widened to $39.7 million, raising funding risks.

Oppenheimer

Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Expectations By $0.11 EPS

CPRX

HRMY

Health care stocks experienced a decline late Thursday, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.7%. Notably, Entrada Therapeutics (TRDA) shares plummeted 57% due to disappointing trial results for a drug aimed at Duchenne muscular dystrophy. Iovance Biotherapeutics (IOVA) shares fell over 13% after a narrower-than-expected Q1 loss and missed revenue estimates. Harmony Biosciences (HRMY) shares dropped 5.5% following disappointing Q1 earnings. Conversely, Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after announcing an acquisition by Angelini Pharma valued at approximately $4.1 billion.

Entrada Therapeutics(TRDA.US)